Ocugen – Consensus Indicates Potential 210.3% Upside

Broker Ratings

Ocugen found using ticker (OCGN) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 1 and 0.7 and has a mean target at 0.9. With the stocks previous close at 0.29 this would indicate that there is a potential upside of 210.3%. The day 50 moving average is 0.31 and the 200 day moving average is 0.34. The market cap for the company is $130m. Find out more information at: http://www.ocugen.com

Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index